Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Feuchtinger, Tobias  [Clear All Filters]
2024
Römer T, Vokuhl C, Staatz G, Mottaghy FM, Christiansen H, Eble MJ, Timmermann B, Klussmann JPeter, Elbracht M, Calaminus G, et al. Combination of nivolumab with standard induction chemotherapy in children and adults with EBV-positive nasopharyngeal carcinoma : Protocol of a prospective multicenter phase 2 trial. HNO. 2024.
Maier C-P, Klose C, Seitz CMartin, Heubach F, Döring M, Meisel R, Schuster FR, Gruhn B, Keller F, Rabsteyn A, et al. Influence of ATLG Serum Levels on CD3/CD19-depleted Hematopoietic Grafts and on Immune Recovery in Pediatric Haplo-HSCT. Blood Adv. 2024.
2023
Flaadt T, Ladenstein RL, Ebinger M, Lode HN, Arnardóttir HBjörk, Poetschger U, Schwinger W, Meisel R, Schuster FR, Döring M, et al. Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial. J Clin Oncol. 2023:JCO2201630.
Bader P, Rossig C, Hutter M, Ayuk FAyuketang, Baldus CD, Bücklein VL, Bonig H, Cario G, Einsele H, Holtick U, et al. CD19-CAR-T cells are an effective therapy of post-transplant relapse in B- ALL patients: Real-World Data from Germany. Blood Adv. 2023.
Vallée T, Schmid I, Gloning L, Bacova M, Ahrens J, Feuchtinger T, Klein C, Gaertner VD, Albert MH. Excellent outcome of stem cell transplantation for sickle cell disease. Ann Hematol. 2023.
Lorenzini T, Cadilha BL, Obeck H, Benmebarek M-R, Märkl F, Michaelides S, Strzalkowski T, Briukhovetska D, Müller PJie, Nandi S, et al. Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy. Br J Cancer. 2023.
Schober S, Rottenberger JM, Hilz J, Schmid E, Ebinger M, Feuchtinger T, Handgretinger R, Lang P, Queudeville M. Th1 cytokines in pediatric acute lymphoblastic leukemia. Cancer Immunol Immunother. 2023.
2021
Stief TA, Kaeuferle T, Müller TR, Döring M, Jablonowski LM, Schober K, Feucht J, Dennehy KM, Willier S, Blaeschke F, et al. Protective T-cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections. Mol Ther. 2021.
2020
Kaeuferle T, Deisenberger L, Jablonowski L, Stief TA, Blaeschke F, Willier S, Feuchtinger T. CRISPR-Cas9-Mediated Glucocorticoid Resistance in Virus-Specific T Cells for Adoptive T Cell Therapy Posttransplantation. Mol Ther. 2020.
2016
Teltschik H-M, Heinzelmann F, Gruhn B, Feuchtinger T, Schlegel P, Schumm M, Kremens B, Müller I, Ebinger M, Schwarze CPhilipp, et al. Treatment of graft failure with TNI-based reconditioning and haploidentical stem cells in paediatric patients. Br J Haematol. 2016.
2015
Günther PS, Peper JK, Faist B, Kayser S, Hartl L, Feuchtinger T, Jahn G, Neuenhahn M, Busch DH, Stevanovic S, et al. Identification of a Novel Immunodominant HLA-B*07: 02-restricted Adenoviral Peptide Epitope and Its Potential in Adoptive Transfer Immunotherapy. J Immunother. 2015;38(7):267-275.